English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 30 November 2023, 16:25 JST
Share:
    

Source: Eisai
Eisai's Sales Subsidiary Collaborates with Ministry of Public Health (MOPH) in Thailand

TOKYO, Nov 30, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that its Thai sales subsidiary Eisai (Thailand) Marketing Co., Ltd., (Eisai Thailand) has made an agreement to collaborate with the Department of Medical Services (DMS), Ministry of Public Health (MOPH) of Thailand to further enhance the access to treatments for dementia including Alzheimer’s disease (AD) in Thailand.

In Thailand, the number of people suffering from dementia is expected to increase significantly from the current 700 thousand to 2 million by 2050 due to the rapid aging of the population.*1 Dementia and AD are the third leading cause of death among women (7.1% of total deaths) and the ninth leading cause of death for men (3.3% of total deaths),*2 making the need to build a system to counter dementia urgent.

With this agreement, Eisai Thailand and DMS have identified three key challenges to addressing issues regarding dementia and AD in Thailand: (1) raising disease awareness for Mild Cognitive Impairment (MCI) and dementia including AD (2) improving diagnosis infrastructure for MCI and dementia including AD and ensuring civilian access to these services (3) ensuring total care by building a dementia community and ecosystem for people with dementia and their families.

Formulation of disease guidelines by the state is essential to address these challenges. Eisai Thailand and DMS will jointly conduct surveys and other initiatives to establish such guidelines. Additionally, both organizations will promote implementation of these guidelines in collaboration with various stakeholders, including those from different industries, to develop an ecosystem dedicated to dementia, seeking to establish a strong support system for the dementia community in Thailand.

Eisai will continue to support people with dementia and their families to “live their fullest lives” to effectively achieve social good in the form of “relieving anxiety over health” and “reducing health disparities”.

(1) Alzheimer’s Disease International. & Alzheimer’s Australia. (2014). Dementia in the Asia Pacific Region. London: Alzheimer’s Disease International.
(2) Burden of Disease Thailand Report 2019

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120



Topic: Press release summary
Source: Eisai

Sectors: BioTech
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Eisai Related News
Wednesday, 20 November 2024, 11:51 JST
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
Wednesday, 20 November 2024, 10:24 JST
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
Friday, 15 November 2024, 17:33 JST
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
Friday, 15 November 2024, 14:31 JST
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
Tuesday, 5 November 2024, 11:35 JST
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
More news >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575